Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated to include a new facility name and location, along with a significant number of study status updates and dates, while some location-related terms have been removed.SummaryDifference76%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check22 days agoChange DetectedThe web page has been updated to a new version, v2.16.11, with the previous version, v2.16.10, being removed. Additionally, a date of August 7, 2025, has been added.SummaryDifference0.6%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
- Check36 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.8%
- Check43 days agoChange DetectedThe web page has been updated to reflect a new version, v2.16.6, and the previous version, v2.16.5, has been removed. Additionally, a date of July 17, 2025, has been added.SummaryDifference0.6%
Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.